Last reviewed · How we verify
Tranexamic Acid / Sodium chloride
Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing bleeding and promoting clot stability.
Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing bleeding and promoting clot stability. Used for Excessive bleeding or hemorrhage (perioperative, trauma, or menorrhagia), Prevention of blood loss in surgical procedures.
At a glance
| Generic name | Tranexamic Acid / Sodium chloride |
|---|---|
| Sponsor | University Hospital, Bordeaux |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Hematology / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
Tranexamic acid is a competitive inhibitor of plasminogen and plasmin, enzymes responsible for breaking down fibrin clots. By preventing fibrin degradation, it stabilizes blood clots and reduces excessive bleeding. The sodium chloride component is a physiological saline carrier for intravenous administration.
Approved indications
- Excessive bleeding or hemorrhage (perioperative, trauma, or menorrhagia)
- Prevention of blood loss in surgical procedures
Common side effects
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Nausea and vomiting
- Diarrhea
- Hypotension
- Visual disturbances
Key clinical trials
- Tranexamic Acid for The Treatment of Gastrointestinal Bleeding (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies (PHASE3)
- Investigating the Efficacy of Tranexamic Acid as a Prophylactic Agent in Reducing Postpartum Hemorrhage Among Patients Undergoing Cesarean Section in SQUH (PHASE3)
- Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults (PHASE3)
- Tranexamic Acid for Bleeding Reduction During TURP Surgery (PHASE4)
- A Trial of Intraoperative Fibrin Sealant on Postoperative Recovery After Total Knee Replacement (PHASE4)
- One Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tranexamic Acid / Sodium chloride CI brief — competitive landscape report
- Tranexamic Acid / Sodium chloride updates RSS · CI watch RSS
- University Hospital, Bordeaux portfolio CI